1. Home
  2. HCAI vs PHGE Comparison

HCAI vs PHGE Comparison

Compare HCAI & PHGE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

HCAI

Huachen AI Parking Management Technology Holding Co. Ltd. Ordinary Shares

HOLD

Current Price

$0.21

Market Cap

11.7M

ML Signal

HOLD

Logo BiomX Inc. COmmon Stock

PHGE

BiomX Inc. COmmon Stock

HOLD

Current Price

$6.37

Market Cap

7.0M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
HCAI
PHGE
Founded
2004
2015
Country
China
United States
Employees
N/A
57
Industry
Miscellaneous manufacturing industries
Biotechnology: Pharmaceutical Preparations
Sector
Consumer Discretionary
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
11.7M
7.0M
IPO Year
N/A
N/A

Fundamental Metrics

Financial Performance
Metric
HCAI
PHGE
Price
$0.21
$6.37
Analyst Decision
Strong Buy
Analyst Count
0
1
Target Price
N/A
$26.00
AVG Volume (30 Days)
415.5K
80.2K
Earning Date
01-01-0001
01-01-0001
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
$63.07
N/A
Revenue Growth
N/A
N/A
52 Week Low
$0.20
$0.25
52 Week High
$10.97
$8.50

Technical Indicators

Market Signals
Indicator
HCAI
PHGE
Relative Strength Index (RSI) 37.07 60.65
Support Level $0.20 $0.41
Resistance Level $0.44 $6.85
Average True Range (ATR) 0.02 0.72
MACD 0.00 -0.08
Stochastic Oscillator 31.45 75.71

Price Performance

Historical Comparison
HCAI
PHGE

About HCAI Huachen AI Parking Management Technology Holding Co. Ltd. Ordinary Shares

Huachen AI Parking Management Technology Holding Co Ltd is a comprehensive smart parking solutions and equipment structural parts provider. The company manufactures and offer various cubic parking garage products by employing various working principles, such as lifting and shifting, convenient lifting, vertical circulation, vertical lifting, plane moving, alley stacking, multi-layer cycle, horizontal cycle, and car lift.

About PHGE BiomX Inc. COmmon Stock

BiomX Inc is engaged in developing both natural and engineered phage cocktails and personalized treatments designed to target and destroy harmful bacteria in chronic diseases, including cystic fibrosis and diabetic foot osteomyelitis. It discovers and validates proprietary bacterial targets and customizes phage compositions against these targets, and applies its BOLT (BacteriOphage Lead to Treatment) platform to customize phage compositions against these targets. BX004 is its therapeutic phage product candidate under development for chronic pulmonary infections caused by Pseudomonas aeruginosa, or P. aeruginosa, a main contributor to morbidity and mortality in patients with CF. Its BX211 - Treatment of Diabetic Foot Osteomyelitis (DFO).

Share on Social Networks: